Salene M W Jones1, Katherine A Guthrie2, Andrea Z LaCroix3, Barbara Sternfeld4, Carol A Landis5, Susan D Reed6, Andrea Dunn4, Bette Caan4, Lee S Cohen7, Julie Hunt2, Katherine M Newton8. 1. Group Health Research Institute, 1730 Minor Ave, Seattle, WA, 98101, USA. wu.582@osu.edu. 2. Fred Hutchinson Cancer Research Center, Seattle, WA, USA. 3. University of California San Diego, San Diego, CA, USA. 4. Kaiser Permanente Division of Research, Oakland, CA, USA. 5. School of Nursing, University of Washington, Seattle, WA, USA. 6. Department of Obstetrics and Gynecology, University of Washington, Seattle, WA, USA. 7. Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA. 8. Group Health Research Institute, 1730 Minor Ave, Seattle, WA, 98101, USA.
Abstract
OBJECTIVE: Research has suggested that the autonomic nervous system (ANS) is involved in the experience of vasomotor symptoms (VMS) during menopause. We examined the relationship of VMS intensity and heart rate variability (HRV), a measure of ANS function. METHODS: Women (n = 282) were recruited from three American states for a clinical trial of yoga, exercise, and omega-3 fatty acid supplements for VMS. To be eligible, women had to report at least 14 VMS per week, with some being moderate to severe. Sitting electrocardiograms were recorded for 15 min using Holter monitors at both baseline and 12-week follow-up. Time and frequency domain HRV measures were calculated. Women completed daily diary measures of VMS frequency and intensity for 2 weeks at baseline and for 1 week at the follow-up assessment 12 weeks later. Multivariable linear regression was used to assess the relationship between VMS and baseline HRV measures and to compare change in HRV with change in VMS over the 12 weeks. RESULTS: Baseline HRV was not associated with either VMS frequency or intensity at baseline. Change in HRV was not associated with change in VMS frequency or intensity across the follow-up. INTERPRETATION: Heart rate variability (HRV) was not associated with basal VMS frequency or intensity in perimenopausal and postmenopausal women experiencing high levels of VMS. Autonomic function may be associated with the onset or presence of VMS, but not with the number or intensity of these symptoms.
OBJECTIVE: Research has suggested that the autonomic nervous system (ANS) is involved in the experience of vasomotor symptoms (VMS) during menopause. We examined the relationship of VMS intensity and heart rate variability (HRV), a measure of ANS function. METHODS: Women (n = 282) were recruited from three American states for a clinical trial of yoga, exercise, and omega-3 fatty acid supplements for VMS. To be eligible, women had to report at least 14 VMS per week, with some being moderate to severe. Sitting electrocardiograms were recorded for 15 min using Holter monitors at both baseline and 12-week follow-up. Time and frequency domain HRV measures were calculated. Women completed daily diary measures of VMS frequency and intensity for 2 weeks at baseline and for 1 week at the follow-up assessment 12 weeks later. Multivariable linear regression was used to assess the relationship between VMS and baseline HRV measures and to compare change in HRV with change in VMS over the 12 weeks. RESULTS: Baseline HRV was not associated with either VMS frequency or intensity at baseline. Change in HRV was not associated with change in VMS frequency or intensity across the follow-up. INTERPRETATION: Heart rate variability (HRV) was not associated with basal VMS frequency or intensity in perimenopausal and postmenopausal women experiencing high levels of VMS. Autonomic function may be associated with the onset or presence of VMS, but not with the number or intensity of these symptoms.
Authors: Hanna Hoikkala; Petri Haapalahti; Matti Viitasalo; Heikki Väänänen; Anssi R A Sovijärvi; Olavi Ylikorkala; Tomi S Mikkola Journal: Menopause Date: 2010-03 Impact factor: 2.953
Authors: Barbara Sternfeld; Katherine A Guthrie; Kristine E Ensrud; Andrea Z LaCroix; Joseph C Larson; Andrea L Dunn; Garnet L Anderson; Rebecca A Seguin; Janet S Carpenter; Katherine M Newton; Susan D Reed; Ellen W Freeman; Lee S Cohen; Hadine Joffe; Melanie Roberts; Bette J Caan Journal: Menopause Date: 2014-04 Impact factor: 3.310
Authors: Barbara Sternfeld; Andrea LaCroix; Bette J Caan; Andrea L Dunn; Katherine M Newton; Susan D Reed; Katherine A Guthrie; Cathryn Booth-LaForce; Karen J Sherman; Lee Cohen; Marlene P Freeman; Janet S Carpenter; Julie R Hunt; Melanie Roberts; Kristine E Ensrud Journal: Contemp Clin Trials Date: 2013-02-24 Impact factor: 2.261
Authors: Susan D Reed; Katherine A Guthrie; Katherine M Newton; Garnet L Anderson; Cathryn Booth-LaForce; Bette Caan; Janet S Carpenter; Lee S Cohen; Andrea L Dunn; Kristine E Ensrud; Ellen W Freeman; Julie R Hunt; Hadine Joffe; Joseph C Larson; Lee A Learman; Robin Rothenberg; Rebecca A Seguin; Karen J Sherman; Barbara S Sternfeld; Andrea Z LaCroix Journal: Am J Obstet Gynecol Date: 2013-11-08 Impact factor: 10.693
Authors: Tatjana Gazibara; Selmina Nurkovic; Nikolina Kovacevic; Ilma Kurtagic; Biljana Rancic; Sanja Radovanovic; Branislav Milosevic; Milan Terzic; Jelena Dotlic Journal: Qual Life Res Date: 2017-06-03 Impact factor: 4.147
Authors: Susan D Reed; Andrea Z LaCroix; Garnet L Anderson; Kristine E Ensrud; Bette Caan; Janet S Carpenter; Lee Cohen; Susan J Diem; Ellen W Freeman; Hadine Joffe; Joseph C Larson; Susan M McCurry; Caroline M Mitchell; Katherine M Newton; Barbara Sternfeld; Katherine A Guthrie Journal: Menopause Date: 2020-04 Impact factor: 2.953